Does Combining a Mobile Dose Calculation App with a Continuous Insulin Infusion System Improve Glycemic Control and Quality of Life Compared with a Hybrid System in Patients with Type 1 Diabetes? A Descriptive Open-Label Sequential Study

Introduction: Achieving optimal glycemic control in patients with type 1 diabetes mellitus (PwT1DM) is essential to prevent complications. Continuous subcutaneous insulin infusion (CSII) systems combined with continuous glucose monitoring (CGM) have improved outcomes, but the effectiveness of additi...

ver descrição completa

Detalhes bibliográficos
Autores: Alarcón, PP, Alvarez, ED, Goitia, CL, Rodríguez, MM, Urbon, L, Maldonado, A, García, S, Serrallonga, NB, Aviño, LR, Palomar, JMR, Lopez, JG, Hoyas, CIN, Corcoy, R, Raimond, TM, López, ML, Madorell, BS, Hernández, M, Kyriakos, G, Bellas, LC, Borrás, JG, Servant, OS, Colet, AM, Serrano, C, Contreras, C, Román, AR, Díez, M, Veladesojo, A, Andujar, P, Diez, A, Galiana, PA, Peris, BP, Fernandez, E, Ferrer, M, Alfonso, FJG, Torre, ELM
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Recursos:Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)
Repositorio:r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
OAI Identifier:oai:isabial.fundanetsuite.com:p11299
Acesso em linha:https://isabial.portalinvestigacion.com/publicaciones11299
Access Level:acceso abierto
Palavra-chave:type 1 diabetes mellitus
hybrid closed-loop systems
continuous subcutaneous insulin infusion
glycemic control
mobile dose calculation apps
continuous glucose monitoring
insulin pump therapy
id ES_aecf8f49209f904c5d615276b49fdf69
oai_identifier_str oai:isabial.fundanetsuite.com:p11299
network_acronym_str ES
network_name_str España
repository_id_str
spelling Does Combining a Mobile Dose Calculation App with a Continuous Insulin Infusion System Improve Glycemic Control and Quality of Life Compared with a Hybrid System in Patients with Type 1 Diabetes? A Descriptive Open-Label Sequential StudyAlarcón, PPAlvarez, EDGoitia, CLRodríguez, MMUrbon, LMaldonado, AGarcía, SSerrallonga, NBAviño, LRPalomar, JMRLopez, JGHoyas, CINCorcoy, RRaimond, TMLópez, MLMadorell, BSHernández, MKyriakos, GBellas, LCBorrás, JGServant, OSColet, AMSerrano, CContreras, CRomán, ARDíez, MVeladesojo, AAndujar, PDiez, AGaliana, PAPeris, BPFernandez, EFerrer, MAlfonso, FJGTorre, ELMtype 1 diabetes mellitushybrid closed-loop systemscontinuous subcutaneous insulin infusionglycemic controlmobile dose calculation appscontinuous glucose monitoringinsulin pump therapyIntroduction: Achieving optimal glycemic control in patients with type 1 diabetes mellitus (PwT1DM) is essential to prevent complications. Continuous subcutaneous insulin infusion (CSII) systems combined with continuous glucose monitoring (CGM) have improved outcomes, but the effectiveness of additional technologies, such as mobile apps and hybrid closed-loop systems (HCLSs), remains unclear. This study evaluates glycemic control and quality of life (QoL) in adult PwT1DM transitioning from multiple daily injections (MDI) to a CSII, first with the Mylife (TM) Dose app and subsequently switching to an HCLS.Materials and Methods: This was a 10-month, multicenter, open-label sequential study involving 135 adults with type 1 diabetes (T1D), all of whom were using isCGM and MDI before transitioning to CSII, first with the Mylife Dose app and later to an HCLS. Glycemic control (glycated hemoglobin [HbA1c], time in range [TIR], time below range, time above range), insulin requirements, and QoL/treatment satisfaction/hypoglycemia perception (Diabetes Quality of Life questionnaire, Diabetes Treatment Satisfaction Questionnaire, Clarke's test) were measured at each of the four study visits.Results: Transitioning from MDI to CSII showed modest improvements in HbA1c (7.57%-7.42%; P = 0.02) and TIR (56.3%-60.4%; P < 0.01). The introduction of the Mylife Dose app did not provide significant additional improvements in glycemic control or QoL, although it provided an additional tool for diabetes management. However, switching to an HCLS resulted in substantial improvements in HbA1c (6.7%), TIR (73.1%), and QoL, with over 70% of patients achieving an HbA1c <7%. Insulin requirements increased slightly with the HCLS, primarily due to basal insulin. Adherence was high, with 88.1% completing the study.Conclusions: The Mylife Dose app does not improve glycemic control or QoL significantly but offers convenience for patients with T1D. In contrast, HCLSs provide significant metabolic and QoL benefits, supporting their integration into T1D management with appropriate reimbursement policies.MARY ANN LIEBERT, INC2025info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://isabial.portalinvestigacion.com/publicaciones11299Diabetes Technology & TherapeuticsISSN: 15209156ISSNe: 15578593reponame:r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicanteinstname:Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)Inglésinfo:eu-repo/semantics/openAccessoai:isabial.fundanetsuite.com:p112992026-06-12T10:20:37Z
dc.title.none.fl_str_mv Does Combining a Mobile Dose Calculation App with a Continuous Insulin Infusion System Improve Glycemic Control and Quality of Life Compared with a Hybrid System in Patients with Type 1 Diabetes? A Descriptive Open-Label Sequential Study
title Does Combining a Mobile Dose Calculation App with a Continuous Insulin Infusion System Improve Glycemic Control and Quality of Life Compared with a Hybrid System in Patients with Type 1 Diabetes? A Descriptive Open-Label Sequential Study
spellingShingle Does Combining a Mobile Dose Calculation App with a Continuous Insulin Infusion System Improve Glycemic Control and Quality of Life Compared with a Hybrid System in Patients with Type 1 Diabetes? A Descriptive Open-Label Sequential Study
Alarcón, PP
type 1 diabetes mellitus
hybrid closed-loop systems
continuous subcutaneous insulin infusion
glycemic control
mobile dose calculation apps
continuous glucose monitoring
insulin pump therapy
title_short Does Combining a Mobile Dose Calculation App with a Continuous Insulin Infusion System Improve Glycemic Control and Quality of Life Compared with a Hybrid System in Patients with Type 1 Diabetes? A Descriptive Open-Label Sequential Study
title_full Does Combining a Mobile Dose Calculation App with a Continuous Insulin Infusion System Improve Glycemic Control and Quality of Life Compared with a Hybrid System in Patients with Type 1 Diabetes? A Descriptive Open-Label Sequential Study
title_fullStr Does Combining a Mobile Dose Calculation App with a Continuous Insulin Infusion System Improve Glycemic Control and Quality of Life Compared with a Hybrid System in Patients with Type 1 Diabetes? A Descriptive Open-Label Sequential Study
title_full_unstemmed Does Combining a Mobile Dose Calculation App with a Continuous Insulin Infusion System Improve Glycemic Control and Quality of Life Compared with a Hybrid System in Patients with Type 1 Diabetes? A Descriptive Open-Label Sequential Study
title_sort Does Combining a Mobile Dose Calculation App with a Continuous Insulin Infusion System Improve Glycemic Control and Quality of Life Compared with a Hybrid System in Patients with Type 1 Diabetes? A Descriptive Open-Label Sequential Study
dc.creator.none.fl_str_mv Alarcón, PP
Alvarez, ED
Goitia, CL
Rodríguez, MM
Urbon, L
Maldonado, A
García, S
Serrallonga, NB
Aviño, LR
Palomar, JMR
Lopez, JG
Hoyas, CIN
Corcoy, R
Raimond, TM
López, ML
Madorell, BS
Hernández, M
Kyriakos, G
Bellas, LC
Borrás, JG
Servant, OS
Colet, AM
Serrano, C
Contreras, C
Román, AR
Díez, M
Veladesojo, A
Andujar, P
Diez, A
Galiana, PA
Peris, BP
Fernandez, E
Ferrer, M
Alfonso, FJG
Torre, ELM
author Alarcón, PP
author_facet Alarcón, PP
Alvarez, ED
Goitia, CL
Rodríguez, MM
Urbon, L
Maldonado, A
García, S
Serrallonga, NB
Aviño, LR
Palomar, JMR
Lopez, JG
Hoyas, CIN
Corcoy, R
Raimond, TM
López, ML
Madorell, BS
Hernández, M
Kyriakos, G
Bellas, LC
Borrás, JG
Servant, OS
Colet, AM
Serrano, C
Contreras, C
Román, AR
Díez, M
Veladesojo, A
Andujar, P
Diez, A
Galiana, PA
Peris, BP
Fernandez, E
Ferrer, M
Alfonso, FJG
Torre, ELM
author_role author
author2 Alvarez, ED
Goitia, CL
Rodríguez, MM
Urbon, L
Maldonado, A
García, S
Serrallonga, NB
Aviño, LR
Palomar, JMR
Lopez, JG
Hoyas, CIN
Corcoy, R
Raimond, TM
López, ML
Madorell, BS
Hernández, M
Kyriakos, G
Bellas, LC
Borrás, JG
Servant, OS
Colet, AM
Serrano, C
Contreras, C
Román, AR
Díez, M
Veladesojo, A
Andujar, P
Diez, A
Galiana, PA
Peris, BP
Fernandez, E
Ferrer, M
Alfonso, FJG
Torre, ELM
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv type 1 diabetes mellitus
hybrid closed-loop systems
continuous subcutaneous insulin infusion
glycemic control
mobile dose calculation apps
continuous glucose monitoring
insulin pump therapy
topic type 1 diabetes mellitus
hybrid closed-loop systems
continuous subcutaneous insulin infusion
glycemic control
mobile dose calculation apps
continuous glucose monitoring
insulin pump therapy
description Introduction: Achieving optimal glycemic control in patients with type 1 diabetes mellitus (PwT1DM) is essential to prevent complications. Continuous subcutaneous insulin infusion (CSII) systems combined with continuous glucose monitoring (CGM) have improved outcomes, but the effectiveness of additional technologies, such as mobile apps and hybrid closed-loop systems (HCLSs), remains unclear. This study evaluates glycemic control and quality of life (QoL) in adult PwT1DM transitioning from multiple daily injections (MDI) to a CSII, first with the Mylife (TM) Dose app and subsequently switching to an HCLS.Materials and Methods: This was a 10-month, multicenter, open-label sequential study involving 135 adults with type 1 diabetes (T1D), all of whom were using isCGM and MDI before transitioning to CSII, first with the Mylife Dose app and later to an HCLS. Glycemic control (glycated hemoglobin [HbA1c], time in range [TIR], time below range, time above range), insulin requirements, and QoL/treatment satisfaction/hypoglycemia perception (Diabetes Quality of Life questionnaire, Diabetes Treatment Satisfaction Questionnaire, Clarke's test) were measured at each of the four study visits.Results: Transitioning from MDI to CSII showed modest improvements in HbA1c (7.57%-7.42%; P = 0.02) and TIR (56.3%-60.4%; P < 0.01). The introduction of the Mylife Dose app did not provide significant additional improvements in glycemic control or QoL, although it provided an additional tool for diabetes management. However, switching to an HCLS resulted in substantial improvements in HbA1c (6.7%), TIR (73.1%), and QoL, with over 70% of patients achieving an HbA1c <7%. Insulin requirements increased slightly with the HCLS, primarily due to basal insulin. Adherence was high, with 88.1% completing the study.Conclusions: The Mylife Dose app does not improve glycemic control or QoL significantly but offers convenience for patients with T1D. In contrast, HCLSs provide significant metabolic and QoL benefits, supporting their integration into T1D management with appropriate reimbursement policies.
publishDate 2025
dc.date.none.fl_str_mv 2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://isabial.portalinvestigacion.com/publicaciones11299
url https://isabial.portalinvestigacion.com/publicaciones11299
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv MARY ANN LIEBERT, INC
publisher.none.fl_str_mv MARY ANN LIEBERT, INC
dc.source.none.fl_str_mv Diabetes Technology & Therapeutics
ISSN: 15209156
ISSNe: 15578593
reponame:r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname:Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)
instname_str Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)
reponame_str r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
collection r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869416612748066816
score 15,223283

Registos relacionados